<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04242927</url>
  </required_header>
  <id_info>
    <org_study_id>NAVI</org_study_id>
    <nct_id>NCT04242927</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Nicotinic Acid on VEGFR Inhibitor-Associated Hand-Foot Skin Reactions</brief_title>
  <official_title>Efficacy of Nicotinic Acid for VEGFR Inhibitor-Associated Hand-Foot Skin Reactions in Solid Tumor Patients: a Randomised Controlled Phase 2 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First People's Hospital of Hangzhou</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial
      Growth Receptor Inhibitor (VEGFRi) in cancer patients. The main purpose of this study is to
      evaluate the efficacy and safety of nicotinic acid in solid tumor patients with grade II/III
      VEGFRi-associated HFSR.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2020</start_date>
  <completion_date type="Anticipated">March 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 9, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate of VEGFR inhibitor-associated hand-foot skin reaction</measure>
    <time_frame>2 year</time_frame>
    <description>Proportion of patients who achieve NCI CTCAE v5.0 - Palmar-Plantar Erythrodysesthesia (PPE) grade 0/1 (enrolled grade 2 patients) or grade 0-2 (enrolled grade 3 patients).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete response rate of VEGFR inhibitor-associated hand-foot skin reaction</measure>
    <time_frame>2 year</time_frame>
    <description>Proportion of patients who achieve NCI CTCAE v5.0 - PPE grade 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose adjustment/withdrawal ratio</measure>
    <time_frame>2 year</time_frame>
    <description>Proportion of patients who need dose adjustment or withdrawal of VEGFR inhibitors, such as sorafenib, regorafenib, anlotinib, and apatinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand-Foot Reaction Quality of Life (HF-QoL)</measure>
    <time_frame>2 year</time_frame>
    <description>Hand-Foot Reaction Quality of Life (HF-QoL) questionnaire, scoring results statistics. The HF-QoL symptom and daily activity total scores were transformed to a scale of 0 to 4, based on the sum of each unit-weighted item score divided by the maximum score. Higher scores on the HF-QoL indicate worse quality of life or greatersymptom burden.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hand-Foot Skin Reaction (HFSR)</condition>
  <arm_group>
    <arm_group_label>Nicotinic acid + Routine care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Routinely apply urea ointment and provide best supportive care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinic acid +Routine care</intervention_name>
    <description>Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.</description>
    <arm_group_label>Nicotinic acid + Routine care</arm_group_label>
    <other_name>Nicotinic Acid 50 MG Oral Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Routine care</intervention_name>
    <description>Routinely apply urea ointment and provide best supportive care.</description>
    <arm_group_label>Routine care</arm_group_label>
    <other_name>Urea ointment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained prior to performing any protocol-related procedures,
             including blood serum collecting

          -  HFSR grade 2 or higher after treatment with VEGFR inhibitors (such as sorafenib,
             regorafenib, anlotinib, and apatinib), according to NCI CTCAE V5.0 - PPE

          -  Age from 18 to 75 years.

          -  Life expectancy of at least 3 months at Day 1

        Exclusion Criteria:

          -  History of allergy to B vitamins

          -  Major surgery or severe traumatic injury, fracture within 4 weeks prior to first dose
             of nicotinic acid or ulceration and any factors that significantly affect oral drug
             absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction

          -  Patient who takes isoniazid in combination with sorafenib and other VEGFR inhibitors.

          -  History of psychiatric drugs substance abuse and fails to quit it or has amental
             disorder

          -  Pregnant or nursing women, fertile patient who is unwilling or unable to use effective
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shenglin Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First People's Hospital of Hangzhou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xueqin Chen, MD</last_name>
    <phone>+8613735430109</phone>
    <email>chenlucy1437@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shenglin Ma, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First People's Hospital of Hangzhou</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xueqin Chen</last_name>
      <phone>+8613735430109</phone>
      <email>chenlucy1437@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Xueqin Chen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shenglin Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

